{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:33:38Z","timestamp":1791894818598,"version":"4.3.4"},"reference-count":52,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"unspecified","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["821283"],"award-info":[{"award-number":["821283"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020624","name":"NIHR Nottingham Biomedical Research Centre","doi-asserted-by":"publisher","award":["IS-BRC-1215-20003"],"award-info":[{"award-number":["IS-BRC-1215-20003"]}],"id":[{"id":"10.13039\/501100020624","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009187","name":"Medical Research Foundation","doi-asserted-by":"publisher","award":["MRF-044-0005-F-TRIV-C0824"],"award-info":[{"award-number":["MRF-044-0005-F-TRIV-C0824"]}],"id":[{"id":"10.13039\/501100009187","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000837","name":"University of Nottingham","doi-asserted-by":"publisher","award":["Anne McLaren Fellowship"],"award-info":[{"award-number":["Anne McLaren Fellowship"]}],"id":[{"id":"10.13039\/501100000837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000282","name":"Sir Jules Thorn Charitable Trust","doi-asserted-by":"publisher","award":["18JTA"],"award-info":[{"award-number":["18JTA"]}],"id":[{"id":"10.13039\/501100000282","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000395","name":"Royal College of Physicians","doi-asserted-by":"publisher","award":["Whitney-Wood Scholarship"],"award-info":[{"award-number":["Whitney-Wood Scholarship"]}],"id":[{"id":"10.13039\/501100000395","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Pfizer Global","award":["Research collaboration WI253942"],"award-info":[{"award-number":["Research collaboration WI253942"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,3,6]]},"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Checkpoint inhibitor-induced liver injury (ChILI) is an immune-related adverse reaction, occurring in patients with cancer receiving immune checkpoint inhibitors (CPI). ChILI is currently managed with high doses of corticosteroids which carry their own risks and potential side effects, and the lack of available biomarkers makes monitoring patients at risk of developing ChILI a challenge. There is no specific test that distinguishes ChILI from other competing diagnoses such as acute autoimmune hepatitis (AIH) and idiosyncratic drug-induced liver injury (DILI) due to other medications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Patients with cancer taking immunotherapy who did and did not develop ChILI were recruited. Patients gave samples during the acute phase of liver injury, before CPI treatment and at 12 weeks following the start of CPI therapy if no toxicity developed. Healthy controls were recruited as well as patients with DILI and AIH. Whole blood was taken for broad immune phenotyping using mass cytometry, peripheral blood mononuclear cells were isolated for validatory flow cytometry and single-cell RNA sequencing (RNA-seq), and plasma was used for cytokine profiling. Samples from a second ChILI cohort were used for validation. Snap-frozen liver biopsies were used for bulk RNA-seq to compare the immune response in ChILI to DILI and AIH and correlate with peripheral immune signals. Formalin-fixed paraffin-embedded liver biopsies were used to visualize liver CD8\n                      <jats:sup>+<\/jats:sup>\n                      T-cell infiltration using confocal microscopy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We have identified a circulating CD8\n                      <jats:sup>+<\/jats:sup>\n                      effector memory T-cell subset, expressing high levels of CD38, HLA-DR and CXCR3 and significantly correlated with alanine transaminase. Flow cytometry and single-cell RNA sequencing revealed an increase in granzyme expression, the liver residency marker CD69 and exhaustion markers CTLA-4, PDCD1 and HAVCR2 relative to other CD8\n                      <jats:sup>+<\/jats:sup>\n                      effector subsets. Liver tissue bulk RNA-seq and immune cell deconvolution showed a significant increase in resident CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells in ChILI compared with DILI and AIH, and a significant upregulation of genes related to CXCR chemokine receptor binding. Plasma cytokine profiling highlighted soluble CD27 and PD-1 as significantly elevated in ChILI relative to controls on CPI.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      We have shown that circulating CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells provide a potential biomarker to distinguish ChILI from DILI and AIH, and highlight different mechanistic pathways between ChILI and other immune-mediated liver injuries.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2025-014178","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T15:50:20Z","timestamp":1774626620000},"page":"e014178","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Circulating exhausted CD8+ effector memory cells differentiate immune checkpoint inhibitor-induced liver injury from other acute immune-mediated liver injuries"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1919-3952","authenticated-orcid":false,"given":"Stuart","family":"Astbury","sequence":"first","affiliation":[{"name":"Nottingham Digestive Diseases Centre, Translational Medical Sciences, School of Medicine, University of Nottingham, Nottingham, UK"},{"name":"NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmond","family":"Atallah","sequence":"additional","affiliation":[{"name":"Nottingham Digestive Diseases Centre, Translational Medical Sciences, School of Medicine, University of Nottingham, Nottingham, UK"},{"name":"NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane I","family":"Grove","sequence":"additional","affiliation":[{"name":"Nottingham Digestive Diseases Centre, Translational Medical Sciences, School of Medicine, University of Nottingham, Nottingham, UK"},{"name":"NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber G","family":"Bozward","sequence":"additional","affiliation":[{"name":"Centre for Liver and Gastrointestinal Research, Institute of Biomedical Research, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK"},{"name":"NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham, Birmingham, UK"},{"name":"Birmingham Advanced Cellular Therapy Facility, University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott P","family":"Davies","sequence":"additional","affiliation":[{"name":"Centre for Liver and Gastrointestinal Research, Institute of Biomedical Research, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK"},{"name":"NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4916-796X","authenticated-orcid":false,"given":"Mark J","family":"Sheehan","sequence":"additional","affiliation":[{"name":"Drug Safety Research and Development, Pfizer Inc, Groton, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven W","family":"Kumpf","sequence":"additional","affiliation":[{"name":"Drug Safety Research and Development, Pfizer Inc, Groton, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessie","family":"Qian","sequence":"additional","affiliation":[{"name":"Drug Safety Research and Development, Pfizer Inc, Groton, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia M","family":"Krajewska","sequence":"additional","affiliation":[{"name":"Centre for Liver and Gastrointestinal Research, Institute of Biomedical Research, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK"},{"name":"NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace E","family":"Wootton","sequence":"additional","affiliation":[{"name":"Centre for Liver and Gastrointestinal Research, Institute of Biomedical Research, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK"},{"name":"NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie R","family":"Lingaya","sequence":"additional","affiliation":[{"name":"Nottingham Digestive Diseases Centre, Translational Medical Sciences, School of Medicine, University of Nottingham, Nottingham, UK"},{"name":"NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davor","family":"Kresnik","sequence":"additional","affiliation":[{"name":"Nottingham Digestive Diseases Centre, Translational Medical Sciences, School of Medicine, University of Nottingham, Nottingham, UK"},{"name":"NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Radulescu","sequence":"additional","affiliation":[{"name":"NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankit","family":"Rao","sequence":"additional","affiliation":[{"name":"Department of Oncology, Nottingham University Hospitals NHS Trust, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hester","family":"Franks","sequence":"additional","affiliation":[{"name":"Department of Oncology, Nottingham University Hospitals NHS Trust, Nottingham, UK"},{"name":"Centre for Cancer Sciences & Biodiscovery Institute, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lourdes","family":"Ruiz-Ortega","sequence":"additional","affiliation":[{"name":"Liver Unit, Department of Internal Medicine, Hospital Universitari Vall d'Hebron, Barcelona, Catalonia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Riveiro-Barciela","sequence":"additional","affiliation":[{"name":"Liver Unit, Department of Internal Medicine, Hospital Universitari Vall d'Hebron, Barcelona, Catalonia, Spain"},{"name":"Department of Medicine, Universitat Aut\u00f2noma de Barcelona, Barcelona, Catalonia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashi K","family":"Ramaiah","sequence":"additional","affiliation":[{"name":"Drug Safety Research and Development, Pfizer Inc, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A","family":"Lanz","sequence":"additional","affiliation":[{"name":"Drug Safety Research and Development, Pfizer Inc, Groton, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changhua","family":"Ji","sequence":"additional","affiliation":[{"name":"Drug Safety Research and Development, Pfizer Inc, La Jolla, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poulam M","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Oncology, Nottingham University Hospitals NHS Trust, Nottingham, UK"},{"name":"Centre for Cancer Sciences & Biodiscovery Institute, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye H","family":"Oo","sequence":"additional","affiliation":[{"name":"Centre for Liver and Gastrointestinal Research, Institute of Biomedical Research, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK"},{"name":"NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guruprasad P","family":"Aithal","sequence":"additional","affiliation":[{"name":"Nottingham Digestive Diseases Centre, Translational Medical Sciences, School of Medicine, University of Nottingham, Nottingham, UK"},{"name":"NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"key":"2026032708501216000_14.3.e014178.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093"},{"key":"2026032708501216000_14.3.e014178.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030"},{"key":"2026032708501216000_14.3.e014178.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690"},{"key":"2026032708501216000_14.3.e014178.4","first-page":"115","article-title":"A new framework for advancing in drug-induced liver injury research","volume":"43","author":"Bj\u00f6rnsson","year":"2023","journal-title":"The Prospective European DILI Registry Liver Int"},{"key":"2026032708501216000_14.3.e014178.5","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s40264-021-01109-4","article-title":"Drug-Induced Liver Injury: Highlights and Controversies in the Recent Literature","volume":"44","author":"Clinton","year":"2021","journal-title":"Drug Saf"},{"key":"2026032708501216000_14.3.e014178.6","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2020.100170","article-title":"Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors","volume":"2","author":"De Martin","year":"2020","journal-title":"JHEP Rep"},{"key":"2026032708501216000_14.3.e014178.7","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2023.100851","article-title":"Incidence, risk factors and outcomes of checkpoint inhibitor-induced liver injury: A 10-year real-world retrospective cohort study","volume":"5","author":"Atallah","year":"2023","journal-title":"JHEP Rep"},{"key":"2026032708501216000_14.3.e014178.8","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005635","article-title":"Systematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse events","volume":"10","author":"Coukos","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026032708501216000_14.3.e014178.9","doi-asserted-by":"crossref","first-page":"102514","DOI":"10.1016\/j.jaut.2020.102514","article-title":"Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development","volume":"114","author":"Regev","year":"2020","journal-title":"J Autoimmun"},{"key":"2026032708501216000_14.3.e014178.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.02.008"},{"key":"2026032708501216000_14.3.e014178.11","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17898"},{"key":"2026032708501216000_14.3.e014178.12","unstructured":"Supportive and palliative care | ESMO. 2023. Available: https:\/\/www.esmo.org\/guidelines\/guidelines-by-topic\/supportive-and-palliative-care\/toxicities-from-immunotherapy"},{"key":"2026032708501216000_14.3.e014178.13","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.58"},{"key":"2026032708501216000_14.3.e014178.14","doi-asserted-by":"publisher","DOI":"10.1016\/J.CELL.2021.04.048"},{"key":"2026032708501216000_14.3.e014178.15","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-44910-2","article-title":"Expression of E-cadherin by CD8+ T cells promotes their invasion into biliary epithelial cells","volume":"15","author":"Davies","year":"2024","journal-title":"Nat Commun"},{"key":"2026032708501216000_14.3.e014178.16","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0114-2"},{"key":"2026032708501216000_14.3.e014178.17","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31759"},{"key":"2026032708501216000_14.3.e014178.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.06.018"},{"key":"2026032708501216000_14.3.e014178.19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1283"},{"key":"2026032708501216000_14.3.e014178.20","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.40695","article-title":"Survival Among Veterans Receiving Steroids for Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy","volume":"6","author":"Van Buren","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2026032708501216000_14.3.e014178.21","doi-asserted-by":"crossref","unstructured":"Piedra-Quintero ZL , Wilson Z , Nava P , et al . CD38: An Immunomodulatory Molecule in Inflammation and Autoimmunity. Front Immunol 2020;11. doi:10.3389\/fimmu.2020.597959","DOI":"10.3389\/fimmu.2020.597959"},{"key":"2026032708501216000_14.3.e014178.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.07.009"},{"key":"2026032708501216000_14.3.e014178.23","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.add1591","article-title":"Clonally expanded CD38hi cytotoxic CD8 T cells define the T cell infiltrate in checkpoint inhibitor-associated arthritis","volume":"8","author":"Wang","year":"2023","journal-title":"Sci Immunol"},{"key":"2026032708501216000_14.3.e014178.24","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00225-23"},{"key":"2026032708501216000_14.3.e014178.25","doi-asserted-by":"publisher","DOI":"10.1038\/nature22367"},{"key":"2026032708501216000_14.3.e014178.26","doi-asserted-by":"crossref","unstructured":"Hellvard A , Zeitlmann L , Heiser U , et al . Inhibition of CDK9 as a therapeutic strategy for inflammatory arthritis. Sci Rep 2016;6. doi:10.1038\/srep31441","DOI":"10.1038\/srep31441"},{"key":"2026032708501216000_14.3.e014178.27","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1111\/jcmm.13414","article-title":"CDK7 inhibition suppresses rheumatoid arthritis inflammation via blockage of NF\u2010\u03baB activation and IL\u20101\u03b2\/IL\u20106 secretion","volume":"22","author":"Hong","year":"2018","journal-title":"J Cellular Molecular Medi"},{"key":"2026032708501216000_14.3.e014178.28","doi-asserted-by":"publisher","DOI":"10.1186\/ar1203"},{"key":"2026032708501216000_14.3.e014178.29","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03233-8"},{"key":"2026032708501216000_14.3.e014178.30","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-020-00653-1"},{"key":"2026032708501216000_14.3.e014178.31","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-024-06535-7","article-title":"Innate and adaptive immune cell interaction drives inflammasome activation and hepatocyte apoptosis in murine liver injury from immune checkpoint inhibitors","volume":"15","author":"Shojaie","year":"2024","journal-title":"Cell Death Dis"},{"key":"2026032708501216000_14.3.e014178.32","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.907591","article-title":"Immune-Mediated Hepatitis During Immune Checkpoint Inhibitor cancer Immunotherapy: Lessons From Autoimmune Hepatitis and Liver Immunology","volume":"13","author":"Hercun","year":"2022","journal-title":"Front Immunol"},{"key":"2026032708501216000_14.3.e014178.33","doi-asserted-by":"publisher","DOI":"10.2174\/1568008053174723"},{"key":"2026032708501216000_14.3.e014178.34","doi-asserted-by":"publisher","DOI":"10.1038\/nature19330"},{"key":"2026032708501216000_14.3.e014178.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.07.021"},{"key":"2026032708501216000_14.3.e014178.36","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1038\/s41591-025-03647-1","article-title":"CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade","volume":"31","author":"Milotay","year":"2025","journal-title":"Nat Med"},{"key":"2026032708501216000_14.3.e014178.37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0246168","article-title":"A novel mouse model for checkpoint inhibitor-induced adverse events","volume":"16","author":"Adam","year":"2021","journal-title":"PLoS One"},{"key":"2026032708501216000_14.3.e014178.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.06.037"},{"key":"2026032708501216000_14.3.e014178.39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0217276","article-title":"Inhibition of immune checkpoints PD-1, CTLA-4, and IDO1 coordinately induces immune-mediated liver injury in mice","volume":"14","author":"Affolter","year":"2019","journal-title":"PLoS One"},{"key":"2026032708501216000_14.3.e014178.40","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27549"},{"key":"2026032708501216000_14.3.e014178.41","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008078","article-title":"Therapeutic inhibition of monocyte recruitment prevents checkpoint inhibitor-induced hepatitis","volume":"12","author":"Gudd","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2026032708501216000_14.3.e014178.42","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0901216"},{"key":"2026032708501216000_14.3.e014178.43","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)62060-3"},{"key":"2026032708501216000_14.3.e014178.44","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-4083"},{"key":"2026032708501216000_14.3.e014178.45","doi-asserted-by":"publisher","DOI":"10.1038\/nri2889"},{"key":"2026032708501216000_14.3.e014178.46","doi-asserted-by":"publisher","DOI":"10.1038\/nm1492"},{"key":"2026032708501216000_14.3.e014178.47","doi-asserted-by":"crossref","first-page":"18017","DOI":"10.1038\/nrdp.2018.17","article-title":"Autoimmune hepatitis","volume":"4","author":"Mieli-Vergani","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"2026032708501216000_14.3.e014178.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2008.12.002"},{"key":"2026032708501216000_14.3.e014178.49","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000239"},{"key":"2026032708501216000_14.3.e014178.50","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ijid.2021.12.325","article-title":"Circulating level of sPD-1 and PD-1 genetic variants are associated with hepatitis B infection and related liver disease progression","volume":"115","author":"Huyen","year":"2022","journal-title":"Int J Infect Dis"},{"key":"2026032708501216000_14.3.e014178.51","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-317071"},{"key":"2026032708501216000_14.3.e014178.52","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2025.101637","article-title":"Fine needle aspirates characterise the hepatocellular carcinoma immune niche to predict immune checkpoint inhibitor outcomes","volume":"8","author":"Aidoo-Micah","year":"2026","journal-title":"JHEP Rep"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-014178","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T15:50:25Z","timestamp":1774626625000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-014178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":52,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,27]]},"published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1136\/jitc-2025-014178"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-014178","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]}}}